We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, for treating adults with moderate-to-severe asthma. The company also provided updates on other pipeline candidates, which are in mid- to late-stage studies for treating various respiratory indications.
Preliminary Data From SNY's Asthma Study on Amlitelimab
Preliminary data from the TIDE-Asthma study showed that treatment with the highest dose level of amlitelimab failed to meet the primary endpoint of the annualized exacerbation rate at week 48 while demonstrating nominal significance at the medium dose level.
At week 60, treatment with the medium dose of amlitelimab demonstrated nominally significant and clinically meaningful reductions in asthma exacerbations, while a numerically greater reduction in exacerbations was observed at the high dose level.
Treatment with amlitelimab led to nominally significant and clinically meaningful improvements in lung function and asthma control – the secondary endpoints of the TIDE-Asthma study.
The phase III studies on the candidate are currently in the planning stage.
Year to date, shares of Sanofi have risen 4.9% against the industry’s decline of 4.9%.
Image Source: Zacks Investment Research
SNY's Progress With Other Respiratory Pipelines
Sanofi is developing itepekimab in partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The candidate is currently being evaluated in two phase III studies — CEREN 1 and CEREN 2 — for treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
A phase II study is evaluating itepekimab in patients with chronic rhinosinusitis without nasal polyps.
Itepekimab is also being investigated in separate mid-to-late-stage studies for the treatment of patients with chronic obstructive pulmonary disease (COPD). Data from these studies are expected to be announced in the second half of 2025.
SNY markets blockbuster asthma drug Dupixent (dupilumab) in collaboration with REGN.
While Sanofi records global net product sales of Dupixent, Regeneron records its share of profit in connection with the global sales of the drug.
Meanwhile, a phase II study is evaluating itepekimab for treating bronchiectasis, with data from the same expected in 2026.
Sanofi is also exploring another candidate, lunsekimig, in separate phase II studies for high-risk asthma and moderate-to-severe asthma. A phase II/III study evaluating lunsekimig in COPD patients is expected to begin later in 2025.
Lunsekimig is also being evaluated in a phase II study for the treatment of CRSwNP. Data from the CRSwNP and asthma studies are expected in 2026.
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share have increased from $22.11 to $23.33 for 2025. During the same time, earnings per share estimates for 2026 have increased from $23.23 to $23.35. Year to date, shares of JAZZ have lost 16.4%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s earnings per share have increased from $5.52 to $7.00 for 2025. During the same time, earnings per share estimates for 2026 have increased from $9.15 to $10.84. Year to date, shares of KRYS have gained 8%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
Sanofi (SNY - Free Report) announced preliminary data from the phase II TIDE-Asthma study, which evaluated its anti-OX40L mAb, amlitelimab, for treating adults with moderate-to-severe asthma. The company also provided updates on other pipeline candidates, which are in mid- to late-stage studies for treating various respiratory indications.
Preliminary Data From SNY's Asthma Study on Amlitelimab
Preliminary data from the TIDE-Asthma study showed that treatment with the highest dose level of amlitelimab failed to meet the primary endpoint of the annualized exacerbation rate at week 48 while demonstrating nominal significance at the medium dose level.
At week 60, treatment with the medium dose of amlitelimab demonstrated nominally significant and clinically meaningful reductions in asthma exacerbations, while a numerically greater reduction in exacerbations was observed at the high dose level.
Treatment with amlitelimab led to nominally significant and clinically meaningful improvements in lung function and asthma control – the secondary endpoints of the TIDE-Asthma study.
The phase III studies on the candidate are currently in the planning stage.
Year to date, shares of Sanofi have risen 4.9% against the industry’s decline of 4.9%.
Image Source: Zacks Investment Research
SNY's Progress With Other Respiratory Pipelines
Sanofi is developing itepekimab in partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The candidate is currently being evaluated in two phase III studies — CEREN 1 and CEREN 2 — for treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
A phase II study is evaluating itepekimab in patients with chronic rhinosinusitis without nasal polyps.
Itepekimab is also being investigated in separate mid-to-late-stage studies for the treatment of patients with chronic obstructive pulmonary disease (COPD). Data from these studies are expected to be announced in the second half of 2025.
SNY markets blockbuster asthma drug Dupixent (dupilumab) in collaboration with REGN.
While Sanofi records global net product sales of Dupixent, Regeneron records its share of profit in connection with the global sales of the drug.
Meanwhile, a phase II study is evaluating itepekimab for treating bronchiectasis, with data from the same expected in 2026.
Sanofi is also exploring another candidate, lunsekimig, in separate phase II studies for high-risk asthma and moderate-to-severe asthma. A phase II/III study evaluating lunsekimig in COPD patients is expected to begin later in 2025.
Lunsekimig is also being evaluated in a phase II study for the treatment of CRSwNP. Data from the CRSwNP and asthma studies are expected in 2026.
SNY's Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Jazz Pharmaceuticals, Inc. (JAZZ - Free Report) and Krystal Biotech, Inc. (KRYS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share have increased from $22.11 to $23.33 for 2025. During the same time, earnings per share estimates for 2026 have increased from $23.23 to $23.35. Year to date, shares of JAZZ have lost 16.4%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s earnings per share have increased from $5.52 to $7.00 for 2025. During the same time, earnings per share estimates for 2026 have increased from $9.15 to $10.84. Year to date, shares of KRYS have gained 8%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.